Search Results
Your search for ,wAS matches 28044 pages
Showing 1 - 50FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
On November 13, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with the antibody-drug conjugate enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for the ...
Broad-Based Genomic Sequencing Associated With Survival Benefit Over Focused Testing for Advanced NSCLC
Patients with non–small cell lung cancer (NSCLC) who received broad-based genomic sequencing in the first-line setting showed improved survival outcomes compared with patients who received testing in the second-line setting or who received focused biomarker testing, according to study findings...
Surgical Resection Associated With Lower Mortality Than SABR in Early-Stage NSCLC
In patients with early-stage non–small cell lung cancer (NSCLC) eligible for either surgery or stereotactic ablative radiotherapy (SABR), surgical resection was associated with significantly lower 3-year all-cause mortality, according to findings from an emulated target trial reported by Kagenaar...
Clinical Trial Participation Among Patients With Advanced Cancer Driven by Structural Factors at Physician and Practice Levels
Physician and oncology practice factors have greater influence over who gets enrolled in advanced cancer clinical trials than measured patient characteristics such as age, cancer type, and physical function, according to a recent study. The findings, published by Jiang et al in JAMA Network Open,...
American Cancer Society Updates Prostate Cancer Screening Guideline
Today, the American Cancer Society (ACS) released an updated guideline for prostate cancer screening. Key changes include a direct recommendation for prostate-specific antigen (PSA)-based screening every 2 years for average-risk men aged 50 to 69 years, with clinicians ensuring patients understand...
Childhood Cancers: Survival Gains Reveal Progress and Persistent Disparities
Survival trends for children and young adults with cancer have improved over the years in the United States, with 5-year overall survival rates reaching 90% in 2017, according to comprehensive findings for U.S. childhood cancer survival statistics published in the Journal of the National Cancer...
Immunochemotherapy Improves Event-Free Survival in Borderline Resectable or Locally Advanced Pancreatic Cancer
According to findings from a randomized phase II trial reported by Bai et al in the Journal of Clinical Oncology, treatment with the immunochemotherapy combination of the PD-1 inhibitor toripalimab and modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and fluorouracil) significantly...
Metastatic Uveal Melanoma: Darovasertib/Crizotinib Evaluated as First-Line Targeted Therapy
In the multicenter phase I/II OptimUM-01 trial, first-line treatment with the protein kinase C inhibitor darovasertib plus the MET inhibitor crizotinib demonstrated antitumor activity and a manageable safety profile in patients with previously untreated metastatic uveal melanoma, suggesting a...
Relapsed or Refractory CTCL: Denileukin Diftitox May Improve HRQoL
Patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) receiving denileukin diftitox-cxdl demonstrated an improvement or maintenance of their overall health-related quality of life (HRQoL), according to findings from Study 302 presented at the European Organisation for Research and...
Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer Risk
Scientists have carried out one of the largest experimental studies of breast cancer variants to date, helping pinpoint genetic changes that are most likely to contribute to the development of the disease. Researchers—led by a team at The Institute of Cancer Research, London—analyzed over 5,000...
KEYNOTE-867: Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
An interim analysis of the phase III KEYNOTE-867 trial published by Jabbour et al in the Journal of Clinical Oncology did not appear to support the combination of stereotactic body radiotherapy (SBRT) and pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC)....
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
In the phase III HEALER trial, first-line treatment with the HER2-targeted bispecific antibody anbenitamab plus albumin-bound docetaxel (HB1801) significantly improved progression-free survival compared with docetaxel, trastuzumab, and pertuzumab (THP) in patients with HER2-positive advanced breast ...
FDA Approves Pimicotinib for Symptomatic TGCT
On November 10, the U.S. Food and Drug Administration (FDA) approved pimicotinib (Pimjetmi), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may cause worsening functional limitation or severe morbidity. MANEUVER Trial Efficacy was...
ASCO and ESMO Issue Joint Consensus Calling for Streamlined Clinical Research Under Updated International Standards
ASCO and the European Society for Medical Oncology (ESMO) have released a joint consensus statement highlighting strategies to reduce administrative burden and streamline cancer clinical trials. The statement focuses on leveraging newly updated guidelines from the International Council for...
Beyond Chemotherapy: Overall Survival Nearly Doubled With Investigational Immunotherapy in Advanced Squamous NSCLC
Updated findings from Stage 1 of the multicenter, international, two-stage phase III PRESERVE-003 trial showed that, among patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease had progressed following anti–PD-(L)1 therapy, treatment with the investigational anti–CTLA-4 ...
Preventing Africa’s Coming Cancer Crisis: The Harm Reduction Imperative
Africa is heading toward a cancer catastrophe, and the oncology community must not look away. Noncommunicable diseases already account for 37% of all deaths in the WHO African Region, up from 24% in 2000, and nearly two-thirds of these deaths occur prematurely, before 70.1,2These are not distant...
First-Line T-DXd: A Change of DESTINY for HER2-Mutant NSCLC?
In patients with advanced HER2-mutant non–small cell lung cancer (NSCLC), first-line monotherapy with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) significantly prolonged progression-free survival compared with standard-of-care chemoimmunotherapy. This was...
Nobel Prize in Physiology or Medicine 2026 Awarded for Optogenetics
The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, MD, PhD, of The Howard Hughes Medical Institute and Stanford University, California; Peter Hegemann, PhD, of Humboldt University of Berlin, Germany; and Georg Nagel,...
U.S. Food and Drug Administration Expanded Indications and Approvals in Bladder and Colorectal Cancers
Several approvals by the U.S. Food and Drug Administration (FDA) over the past month included therapeutics for patients with BCG-unresponsive non–muscle-invasive bladder cancer and locally advanced rectal cancer. Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the FDA...
AI Diagnostics and What Clinicians Can Verify in Oncology
When artificial intelligence (AI) is applied to medical images, it can improve physicians’ diagnostic capabilities as well as identify features that humans are unable to see. From identifying biomarkers to guiding treatment decisions, AI in medical imaging has already demonstrated numerous...
Two ‘Forever Chemicals’ Associated With Higher Risk of ER-Negative Breast Cancer
Higher blood concentrations of two common per- and polyfluoroalkyl substances (PFAS) were associated with an increased incidence of estrogen receptor (ER)-negative breast cancer among women participating in the Sister Study, according to research published by Chang et al in the Journal of Clinical ...
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Treatment with the norepinephrine-dopamine reuptake inhibitor methylphenidate significantly reduced cancer-related fatigue in patients with hematologic malignancies compared with placebo, according to findings from the randomized, double-blind, crossover MICRO trial reported by Frederiksen et al in ...
ROSELLA Subgroup Analysis Supports Relacorilant Use in Patients Previously Treated With Taxanes
Can patients with platinum-resistant ovarian cancer treated with taxane therapy benefit from receiving relacorilant after a taxane? A new subgroup analysis from the phase III ROSELLA trial1 suggests the answer may be yes. The analysis, presented at the 2026 ASCO Annual Meeting, focused on prior...
Extended Follow-up of Nivolumab/Ipilimumab for Localized dMMR/MSI-H Gastric/GEJ Cancer
Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival in patients with localized mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) gastric or gastroesophageal junction (GEJ) adenocarcinoma, based on updated...
Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL
A chemotherapy-free front-line regimen of ponatinib plus blinatumomab significantly improved event-free survival compared with imatinib plus chemotherapy in adults with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Chiaretti et al reported results from...
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC
In the phase III PANKU-Lung01 trial, the bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced nonsquamous non–small cell lung cancer (NSCLC) whose disease had...
FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC
On November 5, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based...
Pediatric Brain Tumors: Prognostic AI Model Guides Precision Therapy Choices
An artificial intelligence (AI) model built based on DNA methylation profiling provided a look at outcomes for children with medulloblastoma and ependymoma, according to study findings published in Nature Genetics. The model may be used to guide personalized treatment decisions, including treatment ...
Anthony B. El-Khoueiry, MD, Named Director of the USC Norris Comprehensive Cancer Center
Anthony B. El-Khoueiry, MD, has been appointed Director of the University of Southern California (USC) Norris Comprehensive Cancer Center, effective November 1. Prior to the appointment, Dr. El-Khoueiry served as Associate Director for Clinical Research, Medical Director of the Clinical...
Keeping PACE With Surgery: SBRT for Localized Prostate Cancer
An updated efficacy analysis of the international phase III PACE-A trial showed high rates of freedom from biochemical or clinical failure (BCF) with both stereotactic body radiation therapy (SBRT) and radical prostatectomy in patients with localized prostate cancer, with no statistically...
HERON-Lung01: HER3-Directed ADC Prolongs Progression-Free Survival in EGFR-Mutated Advanced NSCLC
In the phase III HERON-Lung01 trial, ruzaltatug rezetecan significantly prolonged progression-free survival compared with chemotherapy and showed a manageable safety profile in patients with EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated advanced non–small cell lung cancer (NSCLC),...
Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression
According to results from the phase III SAFFRON trial, the combination of osimertinib and savolitinib significantly improved progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) with MET...
Basser Center for BRCA Awards 2026 Global Prize
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has named Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, as the recipient of...
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
The EGFR and HER3 bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival vs chemotherapy in heavily pretreated Chinese patients with hormone receptor–positive, HER2-negative breast cancer, according to results from the multicenter phase III...
IOF Issues Position Statement on Bone Fragility Management for Patients With MGUS
The International Osteoporosis Foundation (IOF) Committee of Scientific Advisors (CSA) Bone and Cancer Working Group has released a position statement on bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS). The new statement provides guidance on how to...
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
First-line pembrolizumab monotherapy significantly improved progression-free survival compared with carboplatin plus paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer, according to an interim analysis of the phase III...
Perlmutter Cancer Center Names Director of Early-Phase Drug Development and Rare Cancer Programs
NYU Langone Health announced the appointment of Vivek Subbiah, MD, as Director of the Early Phase Drug Development Program and the Rare Cancer Program at NYU Langone’s Perlmutter Cancer Center, effective November 1. He will also serve as Professor in the Department of Medicine’s Division of...
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
Patients preparing to undergo surgery for pancreatic adenocarcinoma who received stereotactic body radiation therapy (SBRT) appeared to have comparable pathologic and surgical outcomes while reporting better quality of life during treatment than those who received conventionally fractionated...
Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control
A hypofractionated radiotherapy regimen was noninferior to conventional radiotherapy for locoregional control among patients with high-risk breast cancer undergoing postmastectomy radiotherapy with internal mammary node irradiation, according to findings from the phase III HypoMast-IMNI trial...
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
Neoadjuvant niraparib monotherapy produced tumor responses and enabled complete resection in selected patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer who were considered unlikely to achieve complete primary debulking surgery. Dan Liu, MD, and colleagues...
Researchers Explore Potential Strategy for Overcoming Resistance to RAS Inhibitors
In a preclinical study published recently in Cancer Research, investigators identified a strategy that may help guide future clinical strategies for overcoming treatment resistance associated with KRAS-targeted cancer therapies. This preclinical study was led by Roswell Park Comprehensive Cancer...
Elizabeth Smyth, MD, on Esophageal/GEJ Cancer: Pembrolizumab or Placebo Plus Concurrent Definitive Chemoradiotherapy
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pembrolizumab in patients with previously untreated locally advanced unresectable esophageal and...
Elizabeth Smyth, MD, on Gastric/GEJ Cancer: Novel CLDN18.2-Targeting ADC
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate arcotatug tavatecan in previously treated patients with gastric or gastroesophageal junction (GEJ)...
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
For patients with relapsed or refractory follicular lymphoma, the timing of progression is one of the factors Peter A. Riedell, MD, considers when choosing the next treatment. A long first remission may support another course of chemoimmunotherapy, but progression within 24 months of starting...
Current Public Knowledge Rates on Alcohol and Cancer Risks
According to a nationally representative survey conducted in October by the Annenberg Public Policy Center of the University of Pennsylvania, the number of Americans aware of the connection between alcohol consumption and an increased risk of cancer has increased to 58%. The policy center has been ...
Phase III VOLGA Trial: Durvalumab/Tremelimumab/Enfortumab Vedotin Improves Outcomes in Bladder Cancer
In the phase III VOLGA trial, researchers evaluated the use of perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy....
OptiTROP-Lung06: A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
In patients with advanced PD-L1–negative nonsquamous non–small cell lung cancer (NSCLC) without targetable genomic alterations, first-line treatment with the Trop-2–directed antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab demonstrated a significant progression-free survival...
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO’s 2018 recommendations and reflects a...
Selpercatinib, Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
Researchers from Vall d’Hebron University Hospital presented advances in targeted therapies for patients with thyroid cancer during the ESMO Congress 2026. Updated results of the phase III LIBRETTO-531 trial showed durable benefits with selpercatinib compared with existing targeted therapies for...
Financial Navigation Program May Help Reduce Cancer-Related Financial Hardship
A financial navigation intervention was associated with significant reductions in financial toxicity among patients with cancer across rural and nonrural oncology practices, according to findings from the Lessening the Impact of Financial Toxicity (LIFT) trial reported by Wheeler et al in the...
